Clinical Trials Browser

Phase 2/3 × INDUSTRY × Thoracic × Clear all

NCT07100080 2026-03-19

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04613596 2026-03-18

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06712316 2026-03-17

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07063745 2026-03-17

MountainTAP-29

Phase 2/3 Recruiting

Lung Neoplasms

NCT07155187 2026-03-11

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT07459751 2026-03-10

A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Phase 2/3 Not yet recruiting

Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

NCT06236438 2026-02-23

LIVIGNO-4

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04619797 2026-02-03

SKYSCRAPER-06

Phase 2/3 Completed

Carcinoma, Non-Small-Cell Lung

NCT06984588 2026-01-30

A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT07365319 2026-01-26

TeLuRide-008

Phase 2/3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05785767 2026-01-22

A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 2/3 Active not recruiting

Advanced Non-Small Cell Lung Cancer

NCT05800015 2026-01-22

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07226999 2026-01-12

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

Phase 2/3 Recruiting

Small Cell Lung Carcinoma

NCT07318883 2026-01-06

A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer

Phase 2/3 Not yet recruiting

Squamous NSCLC

NCT05020769 2025-09-26

SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03653546 2025-09-10

BM

Phase 2/3 Completed

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Respiratory Tract Diseases

NCT07145333 2025-09-08

Drug-SNP

Phase 2/3 Active not recruiting

SCLC

NCT04206072 2025-08-11

D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC

Phase 2/3 Completed

Carcinoma, Non-Small-Cell Lung

NCT06417008 2025-08-01

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT01064466 2025-07-24

Drugs-SNPs

Phase 2/3 Active not recruiting

Neoplasms, Small Cell Lung Carcinoma

NCT05987956 2025-06-06

Drugs-SNPs

Phase 2/3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT00518869 2025-06-04

Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue

Phase 2/3 Terminated

Carcinoma, Non-Small-Cell Lung, Fatigue

NCT06335355 2024-03-28

A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

Phase 2/3 Not yet recruiting

Non-squamous Non-small Cell Lung Cancer

NCT06319313 2024-03-20

Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer

Phase 2/3 Not yet recruiting

Squamous Cell Non-small Cell Lung Cancer

NCT03610360 2024-02-01

DENIM

Phase 2/3 Completed

Other solid neoplasmThoracic

Mesothelioma

NCT02709512 2023-10-04

ATOMIC

Phase 2/3 Completed

249 enrolled 17 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT05001724 2023-04-25

KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent

Phase 2/3 Terminated

Advanced Non-small Cell Lung Cancer

NCT05661240 2022-12-22

Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment

Phase 2/3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT01905657 2021-10-06

MK-3475-010

Phase 2/3 Completed

1,034 enrolled 16 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04750083 2021-02-11

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Phase 2/3 Unknown

Nonsquamous Non-small Cell Lung Cancer

NCT03098030 2020-12-09

Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer

Phase 2/3 Completed

483 enrolled 19 charts

Small Cell Lung Carcinoma

NCT03288870 2020-10-29

DOMINUS

Phase 2/3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT01774578 2020-05-28

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

Phase 2/3 Terminated

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT04254471 2020-02-05

This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients

Phase 2/3 Unknown

Small Cell Lung Carcinoma

NCT02186301 2019-05-07

EGFR

Phase 2/3 Terminated

100 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Recurrence

NCT01907100 2019-03-18

Nintedanib (BIBF 1120) in Mesothelioma

Phase 2/3 Terminated

545 enrolled 15 charts

Other solid neoplasmThoracic

Mesothelioma

NCT02388919 2017-09-18

ALTER0303

Phase 2/3 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT01383148 2017-01-05

TIME

Phase 2/3 Terminated

Carcinoma, Non-Small-Cell Lung

NCT02029209 2016-12-16

To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer

Phase 2/3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT00259064 2016-06-02

INSTEP

Phase 2/3 Completed

NSCLC

NCT01348126 2015-11-05

GALAXY

Phase 2/3 Terminated

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00415818 2014-07-16

Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer

Phase 2/3 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00332280 2013-03-20

Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo

Phase 2/3 Terminated

GastrointestinalGenitourinaryThoracic

Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Genital Neoplasms, Female, Liver Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT00243685 2012-01-26

Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis

Phase 2/3 Completed

BreastGynecologicSarcomaThoracic

Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Sarcoma

NCT00516685 2011-09-30

NSCLC

Phase 2/3 Terminated

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00290953 2008-12-23

SESAME

Phase 2/3 Completed

Lung Neoplasms, Neoplasm Metastasis, Small Cell Lung Carcinoma